1995
Pancreatic adenocarcinoma: CT versus MR imaging in the evaluation of resectability--report of the Radiology Diagnostic Oncology Group.
Megibow A, Zhou X, Rotterdam H, Francis I, Zerhouni E, Balfe D, Weinreb J, Aisen A, Kuhlman J, Heiken J. Pancreatic adenocarcinoma: CT versus MR imaging in the evaluation of resectability--report of the Radiology Diagnostic Oncology Group. Radiology 1995, 195: 327-32. PMID: 7724748, DOI: 10.1148/radiology.195.2.7724748.Peer-Reviewed Original ResearchConceptsComputed tomographyT1-weighted spin-echo sequencesMR imagingPredictive valueSpin-echo sequenceCross-sectional imaging modalitiesInitial imaging assessmentUnresectable pancreatic carcinomaEvaluation of resectabilityAccuracy of CTT2-weighted spin-echo sequencesNegative predictive valuePositive predictive valueMagnetic resonanceAdult patientsOncology GroupHepatic metastasesVascular invasionPathologic resultsPancreatic adenocarcinomaImaging assessmentPancreatic carcinomaCT scanImaging modalitiesAdenocarcinoma
1992
Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate): clinical experience with a new contrast agent.
Rofsky N, Weinreb J. Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate): clinical experience with a new contrast agent. Magnetic Resonance Quarterly 1992, 8: 156-68. PMID: 1390058.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingMn-DPDPN'-dipyridoxylethylenediamineClinical experienceNon-enhanced T1Significant adverse eventsEnhanced magnetic resonance imagingManganese NT2-weighted imagesAdverse eventsHepatocellular originClinical trialsContrast agentsHepatobiliary agentsResonance imagingLiver imagingFavorable resultsLesion detectionNew contrast agentsIssues of safetyImaging techniquesAgentsImagingOptimal methodNumerous strategies